US affiliates of Israel-based Teva Pharmaceutical Industries Ltd on June 9 announced that they have reached an agreement with India's Aurobindo Pharma to resolve a legal patent infringement dispute regarding Teva’s Austedo medicine.
The litigation in the United States will end and Aurobindo will have a licence to sell its Austedo generic product beginning April 2033.
Austedo is the first and only US FDA (Food and Drug Administration)-approved product prescribed for adults for involuntary movements associated with the degenerative Huntington's disease, and for uncontrollable movements in the face, tongue or other body parts, known as tardive dyskinesia.
Shares of Aurobindo Pharma closed 1.44 percent up at Rs 530.45 on June 9.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
